药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
Difenoxin
Daratumumab
The risk or severity of adverse effects can be increased when Daratumumab is combined with Polatuzumab vedotin.
Difenoxin
Antilymphocyte immunoglobulin (horse)
The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with Polatuzumab vedotin.
Difenoxin
Evolocumab
The risk or severity of adverse effects can be increased when Evolocumab is combined with Polatuzumab vedotin.
Difenoxin
Alirocumab
The risk or severity of adverse effects can be increased when Alirocumab is combined with Polatuzumab vedotin.
Difenoxin
Idarucizumab
The risk or severity of adverse effects can be increased when Idarucizumab is combined with Polatuzumab vedotin.
Difenoxin
Asfotase alfa
The risk or severity of adverse effects can be increased when Asfotase alfa is combined with Polatuzumab vedotin.
Difenoxin
Dinutuximab
The risk or severity of adverse effects can be increased when Dinutuximab is combined with Polatuzumab vedotin.
Difenoxin
Anthrax immune globulin human
The risk or severity of adverse effects can be increased when Anthrax immune globulin human is combined with Polatuzumab vedotin.
Difenoxin
Blinatumomab
The risk or severity of adverse effects can be increased when Blinatumomab is combined with Polatuzumab vedotin.
Difenoxin
Dulaglutide
The risk or severity of adverse effects can be increased when Dulaglutide is combined with Polatuzumab vedotin.
Difenoxin
Pembrolizumab
The risk or severity of adverse effects can be increased when Pembrolizumab is combined with Polatuzumab vedotin.
Difenoxin
Nivolumab
The risk or severity of adverse effects can be increased when Nivolumab is combined with Polatuzumab vedotin.
Difenoxin
Vedolizumab
The risk or severity of adverse effects can be increased when Vedolizumab is combined with Polatuzumab vedotin.
Difenoxin
Obinutuzumab
The risk or severity of adverse effects can be increased when Obinutuzumab is combined with Polatuzumab vedotin.
Difenoxin
Raxibacumab
The risk or severity of adverse effects can be increased when Raxibacumab is combined with Polatuzumab vedotin.
Difenoxin
Belimumab
The risk or severity of adverse effects can be increased when Belimumab is combined with Polatuzumab vedotin.
Difenoxin
Ofatumumab
The risk or severity of adverse effects can be increased when Ofatumumab is combined with Polatuzumab vedotin.
Difenoxin
Volociximab
The risk or severity of adverse effects can be increased when Volociximab is combined with Polatuzumab vedotin.
Difenoxin
Denosumab
The risk or severity of adverse effects can be increased when Denosumab is combined with Polatuzumab vedotin.
Difenoxin
Mepolizumab
The risk or severity of adverse effects can be increased when Mepolizumab is combined with Polatuzumab vedotin.